BRAF and neoplasm: Juneja et al. [6] also used two tumor models that are only moderately sensitive to PD-1 blockade, BRAF.PTEN melanoma and B16.F10 melanoma combined with GVAX, to test the relative importance of PD-L1 on tumor cells versus non-tumor cells.